Dr. Aditya Bardia is Assistant Professor at the Medicine Department at Harvard Medical School. He studied medicine at the All India Institute of Medical Sciences in New Delhi, India and later became an Internal Medicine Resident at the Mayo Clinic in Rochester Minnesota. Afterwards he did his fellowship in Clinical Oncology at the Johns Hopkins Kimmel Cancer Center.
Since 2014 he is the Co-Leader of the Molecular and Precision Medicine Tumor Board and since 2017 he became the Director of Precision Medicine Center for Breast Cancer, both at the Massachusetts General Hospital Cancer Center. As well, Dr. Bardia serves at the Scientific Review Committee from Dana – Farber / Harvard Cancer Center, on the ASCO University’s editorial board and ASCO’s Molecular Oncology Tumour Board.
As the Founder Director of Breast Molecular and Precision Therapy (MAP) clinic, he oversees the clinical application of genotyping and targeted therapy trials in breast cancer oncology. Dr. Bardia is the Principal Investigator in several clinical trials investigating the role of targeted therapy combinations for breast cancer and has led the clinical development of novel therapies, including oral endocrine therapies, CDK 4/6 inhibitors-based combinations and sacitumumab.